## ARWR: Arrowhead Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

PARABOLIC warning: MRS_10 at 19.7% exceeds exhaustion threshold (8.0%). Extreme momentum typically precedes mean reversion. Consider profit-taking or tight stops.

- **Horizon:** 1-5 days (momentum)
- **Risk Profile:** High - extreme momentum reversal risk
- **Stop Type:** Fixed 2xATR ($50.67)
- **If Wrong:** Exit on momentum reversal or stop hit
- **Invalidation:** MRS_10 drops below exhaustion threshold

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia**
- Source: Yahoo Finance | 20251202T073000 | Bullish | Relevance: 98%
-  Arrowhead Pharmaceuticals announced that its investigational drug, plozasiran, has received FDA Breakthrough Therapy designation for severe hypertriglyceridemia (SHTG). This designation accelerates the development and review of drugs for serious conditions where preliminary evidence shows substantial improvement over existing therapies. Plozasiran aims to reduce triglyceride levels in adults with SHTG, a condition with limited treatment options that significantly increases the risk of acute pancreatitis.

**2. Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences**
- Source: Business Wire | 20251202T050228 | Somewhat-Bullish | Relevance: 98%
-  Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced its participation in several December 2025 events, including the Piper Sandler and Evercore Healthcare Conferences where they will hold fireside chats. The company will also present at the World Congress of Insulin Resistance, Diabetes and Cardiovascular Disease and the CNS Delivery Summit, highlighting their plozasiran studies and TRiMâ„¢ platform. Presentation materials will be available on their investor relations website.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 8, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | B of A Securiti | $81 | $62 | +31% |
| 2025-12-02 | HC Wainwright & | $85 | $80 | +6% |
| 2025-12-01 | B of A Securiti | $62 | $42 | +48% |
| 2025-12-01 | Chardan Capital | $60 | $60 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | B of A Securiti | main | Buy |
| 2025-12-02 | HC Wainwright & | main | Buy |
| 2025-12-01 | B of A Securiti | main | Buy |
| 2025-12-01 | Chardan Capital | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 3 ($1.64M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 54.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 1 |

**Top Holders:**
- Blackrock Inc.: 14.9% (+4.1%)
- Vanguard Group Inc: 11.8% (+3.3%)
- Avoro Capital Adviso: 8.0% (+2.8%)
- State Street Corpora: 4.7% (+0.4%)
- FMR, LLC: 4.2% (+11.4%)

### Key Risks

1. Elevated short interest (11.1%): bears positioning against stock.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 8 raises (avg +37%) could attract flows.
- Momentum building: MRS_10 improving +7.9% over 5 days suggests accumulation.

### Fundamentals

Balance sheet: strong liquidity (4.9x). Revenue declining -30% YoY, concerning. Analyst sentiment positive (8 raises, avg +37%). Insider selling cluster ($1.6M in 90 days), potential headwind. Institutional flow bullish (8 buying vs 1 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.5B |
| Beta | 1.29 |
| 52W Range | $9.57 - $71.50 |
| Short Interest | 11.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -1.32 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 strengthening from 11.8% to 19.7% (+7.9% in 5 days), confirming momentum buildup. Extended beyond STRENGTH zone (19.7% > 6.0%), caution on chasing. MRS_5 at 6.1% confirms short-term momentum alignment. Outperforming sector by 20.0pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.70), confirming momentum. RSI overbought at 74, risk of mean reversion.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 19.73% (CS: 100) | Strong |
| RSI_14 | 73.6 | Overbought |
| MACD Histogram | 1.70 | Bullish |
| vs SMA20 | 1.323x | Above |
| vs SMA50 | 1.462x | Above |
| vs SMA200 | 2.530x | Above |

### Decision

- **Verdict:** SELL
- **Thesis:** PARABOLIC

### Trade Setup

- **Entry:** $57.95
- **Stop Loss:** $50.67 (12.6% risk)
- **Target:** $65.23 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** PARABOLIC thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 137
- **Position Value:** $7,939.15
- **Portfolio %:** 7.94%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-02-09 (Est: $-0.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.16 | $-0.18 | -14.4% |
| 2025Q2 | $-1.10 | $-1.26 | -14.4% |
| 2025Q1 | $-0.46 | $2.75 | +695.0% |
| 2024Q4 | $-0.72 | $-1.39 | -92.2% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*